BioLineRx Historical Cash Flow
| BLRX Stock | USD 0.32 0.23 41.82% |
Analysis of BioLineRx cash flow over time is an excellent tool to project BioLineRx future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 16 M or Begin Period Cash Flow of 9.4 M as it is a great indicator of BioLineRx ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining BioLineRx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioLineRx is a good buy for the upcoming year.
BioLineRx |
About BioLineRx Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in BioLineRx balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which BioLineRx's non-liquid assets can be easily converted into cash.
BioLineRx Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by BioLineRx to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of BioLineRx operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from BioLineRx's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Change To Netincome is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 22.8 M in 2024, despite the fact that Change In Cash is likely to grow to (6 M).
BioLineRx cash flow statement Correlations
Click cells to compare fundamentals
BioLineRx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioLineRx cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 1.9M | 11.5M | (3.8M) | (2.4M) | (6.3M) | (6.0M) | |
| Stock Based Compensation | 1.8M | 1.3M | 1.5M | 2.2M | 2.3M | 1.6M | |
| Free Cash Flow | (22.7M) | (23.2M) | (23.7M) | (26.6M) | (22.9M) | (24.1M) | |
| Change In Working Capital | 4.3M | (1.3M) | (540K) | 1.2M | 15.2M | 16.0M | |
| Begin Period Cash Flow | 3.4M | 5.3M | 16.8M | 13.0M | 10.6M | 9.4M | |
| Other Cashflows From Financing Activities | 1K | 2.0M | 10.9M | 5K | 3.0M | 3.1M | |
| Depreciation | 940K | 934K | 703K | 654K | 1.4M | 1.5M | |
| Other Non Cash Items | (72K) | 242K | 39K | (5.4M) | 21.9M | 23.0M | |
| Capital Expenditures | 10.2M | 73K | 97K | 316K | 297K | 282.2K | |
| Total Cash From Operating Activities | (22.7M) | (23.2M) | (23.6M) | (26.2M) | (22.6M) | (23.7M) | |
| Net Income | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (57.6M) | |
| Total Cash From Financing Activities | 19.2M | 17.9M | 57.7M | 20.4M | 15.1M | 21.7M | |
| End Period Cash Flow | 5.3M | 16.8M | 13.0M | 10.6M | 4.3M | 8.0M | |
| Change To Liabilities | 3.1M | (773K) | 3.2M | (1.7M) | (564K) | 0.0 | |
| Total Cashflows From Investing Activities | 9.6M | 5.3M | 16.7M | (38.2M) | (34.4M) | (32.7M) | |
| Investments | 5.3M | 16.7M | (38.1M) | 4.0M | 1.4M | 1.5M | |
| Net Borrowings | 9.2M | (1.1M) | (3.4M) | (3.6M) | (3.2M) | (3.1M) | |
| Change To Operating Activities | (934K) | 1.1M | 428K | 24K | 27.6K | 45.1K | |
| Change To Netincome | (73K) | (3.0M) | 6.6M | 3.3M | 3.8M | 4.0M | |
| Issuance Of Capital Stock | 20.3M | 21.2M | 50.4M | 14.4M | 14.1M | 22.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.